Glabellar Lines: Clinical Trials

8 trials for Glabellar Lines, newest first
ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed, 1 active not recruiting, 1 recruiting. 8 Phase 2, 1 Phase 1.

By phase and status

PhaseTrialsStatus
Phase 28Completed 6, Active not recruiting 1, Recruiting 1
Phase 11Completed 1

Follow Glabellar Lines: new trials by email Literature Review of Glabellar Lines trials Research Report on Glabellar Lines

Trials (filtered) newest first · largest first

All 8 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study to Assess the Safety and Efficacy of Co-Reconstituted TrenibotulinumtoxinE and OnabotulinumtoxinA in Adult Participants With Moderate to Severe Upper Facial Lines
TrenibotulinumtoxinE and OnabotulinumtoxinA, Placebo, OnabotulinumtoxinA - Upper Facial Lines, Glabellar Lines		Phase 2RecruitingAbbVie3002026-10-082026-11-05
A Study to Evaluate AI-09 In Participants With Glabellar Lines
AI-09 Ready Use Injectable Botulinum Toxin, Vehicle - Glabellar Lines		Phase 2Active not recruitingEirion Therapeutics Inc.682025-12-032026-01-07
Clinical Trial to Evaluate the Safety and Efficacy of JTM201 to Treat Moderate or Severe Glabellar Lines
JTM201, Placebo - Glabellar Lines		Phase 2CompletedJetema USA Inc.4802024-10-262025-08-29
Phase 2 of HU-045 in Glabellar Lines
HU-045, Xeomin® - Glabellar Lines		Phase 2CompletedHuons Co., Ltd.502022-03-282023-07-05
A Study to the Assess the Change in Condition and Adverse Events of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
OnabotulinumtoxinA X, Placebo - Glabellar Lines		Phase 2CompletedAllergan3282021-10-062025-09-09
A Study of OnabotulinumtoxinA X Injection in Adult Participants With Glabellar Lines
Formulation A: OnabotulinumtoxinA, Formulation B: OnabotulinumtoxinA, Formulation C: OnabotulinumtoxinA - Glabellar Lines		Phase 2CompletedAllergan922021-09-012025-06-27
AGN-151586 Dose-Ranging Study for Treatment of Glabellar Lines
AGN-151586, Placebo - Glabellar Lines		Phase 2CompletedAllergan1982019-09-262023-07-28
The Safety and Efficacy Study of HU-014 Versus Botox® in Subject With Moderate to Severe Glabellar Lines
HU-014 Inj, Botox Inj - Glabellar Lines		Phase 1 / Phase 2CompletedHuons Co., Ltd.572016-09-012018-04-12

Interventions

Botulinum Toxins, Type A (2)  ·  incobotulinumtoxinA (1)

Sponsors

Allergan (3)  ·  Huons Co., Ltd. (2)  ·  AbbVie (1)  ·  Eirion Therapeutics Inc. (1)  ·  Jetema USA Inc. (1)

Countries

United States (6)  ·  South Korea (2)